HP
MRSN

Hikari Power’s Mersana Therapeutics MRSN Stock Holding History

Hikari Power’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,610
Closed -$143K – 116
2019
Q3 		$143K Hold
3,610
– – 0.02% 114
2019
Q2 		$365K Hold
3,610
– – 0.04% 82
2019
Q1 		$475K Buy
3,610
+194
+6% +$24.4K 0.05% 74
2018
Q4 		$348K Buy
+3,416
New +$540K 0.04% 77

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Hikari Power's MRSN Position: Q4 2019 in Review

Hikari Power sold out of Mersana Therapeutics (MRSN) in Q4 2019, closing a stake of 3,610 shares — an estimated $143K sold.

Hikari Power first reported a position in MRSN in Q4 2018 and held it in 4 quarters. The position peaked at $475K in Q1 2019. 69 funds tracked by Wall St. Rank hold MRSN as of Q4 2019.

  • Hikari Power reported no remaining Mersana Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Hikari Power sold 3,610 Mersana Therapeutics shares in Q4 2019, an estimated $143K.
  • Hikari Power first reported a position in Mersana Therapeutics in Q4 2018 and held it in 4 quarters.
  • Hikari Power's Mersana Therapeutics position peaked at $475K in Q1 2019.
  • 69 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2019.

Based on Hikari Power's 13F filing for Q4 2019, filed 4 Feb 2020.